Cargando…

Microfluidic chip‐based single‐cell cloning to accelerate biologic production timelines

Cell line development (CLD) represents a critical, yet time‐consuming, step in the biomanufacturing process as significant resources are devoted to the scale‐up and screening of several hundreds to thousands of single‐cell clones. Typically, transfected pools are fully recovered from selection and c...

Descripción completa

Detalles Bibliográficos
Autores principales: Diep, Jonathan, Le, Huong, Le, Kim, Zasadzinska, Ewelina, Tat, Jasmine, Yam, Pheng, Zastrow, Ryan, Gomez, Natalia, Stevens, Jennitte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285370/
https://www.ncbi.nlm.nih.gov/pubmed/34323013
http://dx.doi.org/10.1002/btpr.3192
_version_ 1784747761270259712
author Diep, Jonathan
Le, Huong
Le, Kim
Zasadzinska, Ewelina
Tat, Jasmine
Yam, Pheng
Zastrow, Ryan
Gomez, Natalia
Stevens, Jennitte
author_facet Diep, Jonathan
Le, Huong
Le, Kim
Zasadzinska, Ewelina
Tat, Jasmine
Yam, Pheng
Zastrow, Ryan
Gomez, Natalia
Stevens, Jennitte
author_sort Diep, Jonathan
collection PubMed
description Cell line development (CLD) represents a critical, yet time‐consuming, step in the biomanufacturing process as significant resources are devoted to the scale‐up and screening of several hundreds to thousands of single‐cell clones. Typically, transfected pools are fully recovered from selection and characterized for growth, productivity, and product quality to identify the best pools suitable for single‐cell cloning (SCC) using limiting dilution or fluorescence‐activated cell sorting (FACS). Here we report the application of the Berkeley Lights Beacon Instrument (BLI) in an early SCC process to accelerate the CLD timeline. Transfected pools were single‐cell cloned when viabilities reached greater than 85% or during selection when viabilities were less than 30%. Clones isolated from these accelerated processes exhibited comparable growth, productivity, and product quality to those derived from a standard CLD process and fit into an existing manufacturing platform. With these approaches, up to a 30% reduction in the overall CLD timeline was achieved. Furthermore, early process‐derived clones demonstrated equivalent long‐term stability compared with standard process‐derived clones over 50 population doubling levels (PDLs). Taken together, the data supported early SCC on the BLI as an attractive approach to reducing the standard CLD timeline while still identifying clones with acceptable manufacturability.
format Online
Article
Text
id pubmed-9285370
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-92853702022-07-15 Microfluidic chip‐based single‐cell cloning to accelerate biologic production timelines Diep, Jonathan Le, Huong Le, Kim Zasadzinska, Ewelina Tat, Jasmine Yam, Pheng Zastrow, Ryan Gomez, Natalia Stevens, Jennitte Biotechnol Prog RESEARCH ARTICLES Cell line development (CLD) represents a critical, yet time‐consuming, step in the biomanufacturing process as significant resources are devoted to the scale‐up and screening of several hundreds to thousands of single‐cell clones. Typically, transfected pools are fully recovered from selection and characterized for growth, productivity, and product quality to identify the best pools suitable for single‐cell cloning (SCC) using limiting dilution or fluorescence‐activated cell sorting (FACS). Here we report the application of the Berkeley Lights Beacon Instrument (BLI) in an early SCC process to accelerate the CLD timeline. Transfected pools were single‐cell cloned when viabilities reached greater than 85% or during selection when viabilities were less than 30%. Clones isolated from these accelerated processes exhibited comparable growth, productivity, and product quality to those derived from a standard CLD process and fit into an existing manufacturing platform. With these approaches, up to a 30% reduction in the overall CLD timeline was achieved. Furthermore, early process‐derived clones demonstrated equivalent long‐term stability compared with standard process‐derived clones over 50 population doubling levels (PDLs). Taken together, the data supported early SCC on the BLI as an attractive approach to reducing the standard CLD timeline while still identifying clones with acceptable manufacturability. John Wiley & Sons, Inc. 2021-08-10 2021 /pmc/articles/PMC9285370/ /pubmed/34323013 http://dx.doi.org/10.1002/btpr.3192 Text en © 2021 Amgen Inc. Biotechnology Progress published by Wiley Periodicals LLC on behalf of American Institute of Chemical Engineers. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle RESEARCH ARTICLES
Diep, Jonathan
Le, Huong
Le, Kim
Zasadzinska, Ewelina
Tat, Jasmine
Yam, Pheng
Zastrow, Ryan
Gomez, Natalia
Stevens, Jennitte
Microfluidic chip‐based single‐cell cloning to accelerate biologic production timelines
title Microfluidic chip‐based single‐cell cloning to accelerate biologic production timelines
title_full Microfluidic chip‐based single‐cell cloning to accelerate biologic production timelines
title_fullStr Microfluidic chip‐based single‐cell cloning to accelerate biologic production timelines
title_full_unstemmed Microfluidic chip‐based single‐cell cloning to accelerate biologic production timelines
title_short Microfluidic chip‐based single‐cell cloning to accelerate biologic production timelines
title_sort microfluidic chip‐based single‐cell cloning to accelerate biologic production timelines
topic RESEARCH ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285370/
https://www.ncbi.nlm.nih.gov/pubmed/34323013
http://dx.doi.org/10.1002/btpr.3192
work_keys_str_mv AT diepjonathan microfluidicchipbasedsinglecellcloningtoacceleratebiologicproductiontimelines
AT lehuong microfluidicchipbasedsinglecellcloningtoacceleratebiologicproductiontimelines
AT lekim microfluidicchipbasedsinglecellcloningtoacceleratebiologicproductiontimelines
AT zasadzinskaewelina microfluidicchipbasedsinglecellcloningtoacceleratebiologicproductiontimelines
AT tatjasmine microfluidicchipbasedsinglecellcloningtoacceleratebiologicproductiontimelines
AT yampheng microfluidicchipbasedsinglecellcloningtoacceleratebiologicproductiontimelines
AT zastrowryan microfluidicchipbasedsinglecellcloningtoacceleratebiologicproductiontimelines
AT gomeznatalia microfluidicchipbasedsinglecellcloningtoacceleratebiologicproductiontimelines
AT stevensjennitte microfluidicchipbasedsinglecellcloningtoacceleratebiologicproductiontimelines